Melatonin decreases bone marrow and lymphatic toxicity of adriamycin in mice bearing TLX5 lymphoma

Life Sciences

Volumn 63, Issue 19, 1998, Pages 1701-1713

  Rapozzi, Valentina ^a   Zorzet, Sonia ^b   Comelli, Marina ^a   Mavelli, Irene ^a   Perissin, Laura ^a   Giraldi, Tullio ^a,b  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Adriamycin antitumor activity; Adriamycin toxicity; Bone marrow; Melatonin; Splenic T lymphocyte subsets

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; DOXORUBICIN; GLUTATHIONE; MALONALDEHYDE; MELATONIN; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BONE MARROW TOXICITY; COLONY FORMING UNIT GM; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIPID PEROXIDATION; LYMPHATIC SYSTEM DISEASE; LYMPHOMA; MALE; MOUSE; NONHUMAN; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIOXIDANTS; BONE MARROW DISEASES; DOXORUBICIN; GLUTATHIONE; LIPID PEROXIDATION; LYMPHATIC DISEASES; LYMPHOMA; MALE; MELATONIN; MICE; MICE, INBRED CBA; NEOPLASM TRANSPLANTATION; T-LYMPHOCYTES; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

ANIMALIA;

EID: 0032476164     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(98)00442-1     Document Type: Article

References (77)

1. 1. P. ENGEL 4 281-291 (1934).
2. 2. P. ENGEL. Z. Krebsforsch. 41 488-496 (1935).
3. 3. R. HOFSTATTER. 62 338-339 (1950).
4. 4. A.E. RODIN. 23 1545-1550 (1963).
5. 5 R.M. BARONE and T.K. DAS GUPTA. J. Surg. Oncol. 2 313-322 (1970).
6. 6 T.K. DAS GUPTA and J. TERZ. Cancer Res. 27 1306-1311 (1967).
7. 7. V. LAPIN. Exp. Pathol. 9 108-112 (1974).
8. 8 H. WRBA, V. LAPIN and V. DOSTAL. Osterreichische Z. Onkol. 2 37-39 (1975).
9. 9. A.A. EL-DOMEIRI and T.K DAS GUPTA. Cancer Res. 33 2830-2833 (1973).
10. 10. A.A. EL-DOMEIRI and T.K. DAS GUPTA. J. Surg. Oncol. 8 197-205 (1976).
11. 11. C. AUBERT, P. JANIAUD and J. LECALVEZ. J. Neural Transm. 47 121-130 (1980).
12. 12. T. NARITA and H. KUDO. Cancer Res. 45 4175-4177 (1985).
13. 13 W. REGELSON and W. PIERPAOLI. Cancer Invest. 5 379-385 (1987).
14. 14. D.E. BLASK. Melatonin: Biosynthesis, physiological effects, and chemical applications, H. S. Yu and R. J. Reiter (Eds), 447-477, CRC Press, Boca Raton Florida (1993).
15. 15. S.M. HILL and D.E. BLASK. Cancer Res. 48 6121-6126 (1988).
16. 16. S. COS, F. FERNANDEZ and E.J. SANCHEZ-BARCELO Life Sci. 58 2447-2453 (1996).
17. 17. T. HAMILTON. Br. J. Surg. 56 764-766 (1969).
18. 18. L.R. STANBERRY, T.K. DAS GUPTA and C.W. BEATTLLE. Endocrinology 113 469-475 (1983).
19. 19. G.J.M. MAESTRONI. J. Pineal Res. 14 1-10 (1993).
20. 20. A. ANGELI, G. GATTI, M.L. SARTORI and R.G. MASERA. Chronobiologia 19 93-110 (1992).
21. 21. M.C. CAROLEO, D. FRASCA, G. NISTICÒ' and G. DORIA. Immunopharmacology 23 81-89 (1992).
22. 22. M. KARASEK and F. FRASCHINI. Role of melatonin and pineal peptides in neuroimmunomodulation, F. Fraschini and R.J. Reiter (Eds), 243-251, Plenum Press, New York (1993).
23. 23. P. LISSONI, S. BARNI, G. CATTANEO, G. TANCINI, G. ESPOSTI and F. FRASCHINI. Oncology 48 448-450 (1991).
24. 24. P. LISSONI, S. BARNI, A. ARDIZZOIA, G. TANCINI, A. CONTI and G.J.M. MAESTRONI. Cancer 73 699-701 (1994).
25. 25. P. LISSONI, S. BARNI, G. TANCINI, A. ARDIZZOIA, G. RICCI, R. ALDEGHI, F. BRIVIO, E. TISI, F. ROVELLI, R. RESCALDANI, G. QUADRO and G.J.M. MAESTRONI. Br. J. Cancer 69 196-199 (1994).
26. 26. P. LISSONI, S. BARM, G. TANCINI, E. MAININI, F. PIGLIA, G.J.M. MAESTRONI and A. LEWINSKY. Oncology 52 163-166 (1995).
27. 27. S.M. WEBB and M. PUIG-DOMINGO. Clin. Endocrinol (Oxf). 42 221-234 (1995).
28. 28. G.J.M. MAESTRONI. J. Pineal Res. 18 84-89 (1995).
29. 29. G.J.M. MAESTRONI, E. HERTENS, P. GALLI, A. CONTI and E. PEDRINIS. J. Pineal Res. 21 131-139 (1996).
30. 30. D.X. TAN, L.D. CHEN, B. POEGGELER, L.C. MANCHESTER and R.J. REITER. Endocrine J. 1 57-60 (1993).
31. 31. E. SEWERYNEK, B. POEGGELER, D. MELCHIORRI and R.J. REITER. Neurosci. Lett. 195 203-205 (1995).
32. 32. C. PIERI, M. MARRA, F. MORONI, R. RECCHIONI and F. MARCHESELLI. Life Sci. 15 PL271-PL276 (1994).
33. 33. L.R. BARLOW-WALDEN, R.J. REITER, M. ABE, M. PABLOS, A. MENENDEZ-PELAEZ, L.D. CHEN and B. POEGGELER. Neurochem. Int. 26 497-502 (1995).
34. 34. E. SEWERYNEK, M. ABE, R.J. REITER, L.R. BARLOW-WALDEN, L.D. CHEN, J.J. MCCABE, L.Y. ROMAN and B. DIAZ-LOPEZ. J. Cell. Biochem. 58 436-444 (1995).
35. 35. VIJAYALAXMI, R.J. REITER and M.L. MELTZ.Mutat. Res. 346 23-31 (1995).
36. 36. M. ABE, R.J. REITER, P.B. ORHII, M. HARA and B. POEGGELER. J. Pineal Res. 17 94-100 (1994).
37. 37. Z.R. LI, R.J. REITER, O. FUJIMORI, C.S. OH and Y.P. DUAN. J. Pineal Res. 22 117-123 (1997).
38. 38. D.X. TAN, R.J. REITER, L.D. CHEN, B. POEGGELER, L.C. MANCHESTER and L.R. BARLOW-WALDEN. Carcinogenesis 15 215-218 (1994).
39. 39. P. GIUSTI, D. FRANCESCHINI, M. PETRONJE, H. MANEV and M. FLOREANI. J. Pineal Res. 20 226-231 (1996).
40. 40. M.E. BILLINGHAM, J.W. MASON, M.R. BRISTOW and J.R. DANIELS. Cancer Treat. Rep. 62 865-872 (1978).
41. 41. R.K. SINGAL, M.R. DEALLY and L.E. WEINBERG. J. Mol. Cell. Cardiol. 19 817-828 (1987).
42. 42. B.K. SINHA and P.M. POLITI. Cancer Chemother Biol. Resp. Modifiers Annu. 11 45-57 (1990).
43. 43. R.D. OLSON and P.S. MUSHLIN. FASEB J. 4 3076-3086 (1990).
44. 44. S.C. MYERS. Cancer Chemother. Biol. Resp. Modifiers Annu. 10 33-39 (1988).
45. 45. H. ITO, S.C. MILLER, M.E. BILLINGHAM, H. AKIMOTO, S.V. TORTI, R. WADE, R. GAHLMANN, G. LYONS, L. KEDES, and F.M. TORTI. Proc Natl Acad Sci. USA 87 4275-4279 (1990).
46. 46. S.V. HUNT. Lymphocytes a practical approach, C.G.B. Klaus (Ed), 1-34, IRL Press, Oxford (1987).
47. 47. G. DASIC, S. PACOR, A. BERGAMO, G. SALERNO, B. VRANESIC, R. JUKIC, I. TOMASIC and G. SAVA. Int. J. Oncol. 5 275-284 (1994).
48. 48. D.J. REED, J.R. BABSON, P.W. BEATTY, A.E. BRODIE, W. ELLIS and D.W. POTTER. Anal. Biochem. 106 55-62 (1980).
49. 49. O.H. LOWRY, N.S. ROSEBROUGH, A.L. FAN and R.J. RANDALL. J. Biol. Chem. 193 265-275 (1951).
50. 50. M. UCHIYAMA and M. MIHARA. Anal. Biochem. 193 265-275 (1978).
51. 51. S.H.Y. WONG, J.A. KNIGHT, S.M. HOPFER, O. ZAHARIA, C.N. LEACH and W. SUNDERMAN. Anal. Biochem. 193 265-275 (1987).
52. 52. SYSTAT for DOS: Quick Reference, Version 6 Edition, SYSTAT Inc., Evanston IL (1994).
53. 53. D.E. BLASK, S.T. WILSON and A.M. LEMUS-WILSON. Avances in Pineal Research, G.J.M. Maestroni, A. Conti and R.J. Reiter (Eds), 235-241, John Libbey & Company Ltd, London (1994).
54. 54. N. ZISAPEL and M. BUBIS. Advances in Pineal Research, G.J. M. Maestroni, A. Conti and R.J. Reiter (Eds), 259-267, John Libbey & Company Ltd, London (1994).
55. 55. D.E. BARTSCH, C. BARTSCH, D. MECKE and T.H. LIPPERT. Advances in Pineal Research, G.J.M. Maestroni, A. Conti and R.J. Reiter (Eds), 247-252, John Libbey & Company Ltd, London (1994).
56. 56. G. PIERREFICHE, G. TOPALL, I. COURBOIN, I. HENRIET, I. and H. LABORIT. Res. Comm. Chem. Pathol. Pharmacol. 80 211-223 (1993).
57. 57. G.J.M. MAESTRONI, V. COVACCI and A. CONTI. Cancer Res. 54 2429-2432 (1994).
58. 58. G.J.M. MAESTRONI, A. CONTI and P. LISSONI. Cancer Res. 54 4740-4743 (1994).
59. 59. G.J.M. MAESTRONI, L. FLAMIGNI, E. HERTENS and A. CONTI. Neuroendocrinol. Lett. 17 145-152 (1995).
60. 60. G.J.M. MAESTRONI AND A. CONTI. Neuroimmunomodulation 3 325-332 (1996).
61. 61. Y.M. WANG, F.F. MADANAT, J.L. KIMBALL, C.A. GLEISER, M.K. ALI, M.W. KAUFAM and J. EYS. Cancer Res. 40 1022-1027 (1980).
62. 62. A.L. SAGONE and G.M. BURTON Jr. Am. J. Hematol. 7 97-106 (1979).
63. 63. J.H. DOROSHOW, S. AKMAN, F.F. CHU and S. ESWORTHY. Pharmac.Ther. 47 359-370 (1990).
64. 64. D.L. GUSTAFSON, J.D. SWANSON and C.A. PRITSOS. Free Rad. Res. Commun. 19 111-120 (1993).
65. 65. R.J. REITER, L. TANG, J.J. GARCIA and A. MUNOZ-HOYOS. Life Sci. 60 2255-2271 (1997).
66. 66. Z. MATUSZAK, K.J. RESZKA and C.F. CHIGNELL. Free Radical Biol. Med. 23 367-372 (1997).
67. 67. I. MAVELLI, M.R. CIRIOLO, L. DINI, and G. ROTILIO. Superoxide and Superoxide Dismutase in Chemistry, Biology and Medicine, G. Rotilio (Ed), 425-428, Elsevier Science Publishers B.V., Amsterdam (1986).
68. 68. A.L. ODOM, C.A. HATWIG, J.S. STANLEY and A.M. BENSON Biochem. Pharmacol. 43 831-836 (1992).
69. 69. T. SIMIC, J. MIMIC-OKA AMD M. SINDJIC. Srp. Arh. Celok Lek. 124 45-47 (1996).
70. 70. N.S. PARANKA and R.T. DORR. Anticancer Res. 14 2047-2052 (1994).
71. 71. P. MONTILLA, I. TÙNEZ, M.C. MUNOZ, A. LÒPEZ AND J.V. SORIA Nephron 76 345-350 (1997).
72. 72. N.R. BACHER, S.L. GRODEN and M.V. GEE. Mol. Pharmacol. 13 901-910 (1977).
73. 73. R.D. OLSON, R.C. BOERTH, J.G. GERBER and A.S. NIES. Life Sci. 29 1393-1401 (1981).
74. 74. E.G. MIMNAUGH, M.A. TRUTH, M. BHATNAGAR, and T.E. GRAM. Biochem. Pharmacol. 34 847-856 (1985).
75. 75. D. NOWAK AND J. DRZEWOSKI. The Cancer Journal 9 296-303 (1996).
76. 76. Y. SADZUKA and Y. TAKINO. Toxicology Letters 61 49-56 (1992).
77. 77. W.J.M. HRUSHESKY and G.A. BJARNASON. Cancer-Principles & Pratice in Oncology, V.T. De Vita jr, S. Helmann and G.A. Rosenberg (Eds), 2666-2686, Lippincott (1993).